US Molecular Cytogenetics Market (2025-2030)
The US Molecular Cytogenetics Market was valued at $182.6 Million in 2025 and projected to reach to $260.5 Million by 2030, representing a compound annual growth rate of 7.4%. The US Molecular Cytogenetics Market is positioned for sustained growth through 2030, driven by technological advancements in fluorescence in situ hybridization (FISH), array-based CGH, and next-generation sequencing platforms.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Molecular Cytogenetics Market Trends and Insights
- This growth trajectory reflects the US healthcare sector's increasing adoption of advanced diagnostic technologies for genetic and chromosomal abnormality detection.
- The US market benefits from robust healthcare infrastructure, high diagnostic spending, and strong demand for precision medicine solutions across oncology, prenatal diagnosis, and hematology applications. Driving expansion in the US market are rising cancer incidence rates, growing awareness of genetic testing benefits, and accelerating clinical laboratory automation.
- The US maintains leadership in molecular diagnostics innovation, with significant investments from both public and private sectors supporting technology advancement.
- By 2030, the US Molecular Cytogenetics Market is expected to capture substantial value as healthcare providers increasingly integrate these diagnostic tools into routine clinical workflows..
Key Market Statistics
- CAGR (2025-2030) 7.4% CAGR
- Market Size, 2025 ~USD 182.6 Million
- Forecast, 2030 ~USD 260.5 Million
- Country US
US Molecular Cytogenetics Market Overview
Market Valuation :
The US Molecular Cytogenetics Market is valued at $182.6 million in 2025, with strong growth momentum driven by increasing demand for advanced genetic diagnostic solutions across clinical laboratories and healthcare institutions.
Robust Growth Trajectory :
The US market is projected to reach $260.5 million by 2030, representing a 7.4% CAGR, outpacing the global growth rate of 7.1% and reflecting the region's leadership in healthcare innovation and adoption.
Advanced Healthcare Infrastructure :
The US benefits from well-established diagnostic networks, high healthcare spending, and strong regulatory frameworks that accelerate the adoption of molecular cytogenetics technologies in clinical practice.
Genetic Testing Demand :
Rising prevalence of genetic disorders, increased prenatal and cancer screening initiatives, and growing awareness of personalized medicine are driving significant demand for molecular cytogenetics solutions across US healthcare systems.
US Molecular Cytogenetics Market Dynamics
- Healthcare providers are increasingly integrating these diagnostic tools into routine clinical workflows for cancer diagnosis, prenatal screening, and genetic disorder detection, supported by favorable reimbursement policies and insurance coverage expansion. Key growth catalysts include rising cancer incidence rates, expanding newborn screening programs, and growing adoption of precision medicine approaches across US hospitals and diagnostic laboratories.
- Investment in healthcare infrastructure, coupled with increasing collaboration between academic medical centers and commercial diagnostic providers, will further accelerate market penetration and drive innovation in molecular cytogenetics technologies through the forecast period..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The US Molecular Cytogenetics Market is valued at $182.6 million in 2025 and will reach $260.5 million by 2030, growing at 7.4% CAGR.
- The US market is driven by rising cancer prevalence, increased genetic testing adoption, and strong healthcare infrastructure investment.
- The US leads in molecular diagnostics innovation with significant public and private sector R&D funding supporting market expansion.
- By 2030, the US market will see accelerated integration of molecular cytogenetics into routine clinical diagnostics and precision medicine workflows.
Molecular Cytogenetics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | PROBES (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 7.1% from 2025 to 2030 |
| Largest Segment | KITS & REAGENTS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 1.01 (2025) |
| Revenue Forecast (Billions) | ~USD 1.43 (2030) |
| Segments Covered | Product & Service, Type |
US Molecular Cytogenetics Market Report Segmentation
2 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Kits & Reagents
- Software & Services
By Type
- Fluorescent Affinity Reagents
- Other Kits & Reagents
- Probes
- Testing Kits
US: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 87.9 | 90.8 | 94.8 | 100.9 | 107.4 | 114.6 | 122.9 | 132.4 | 6.9 |
| CLINICAL & DIAGNOSTIC LABORATORIES | 186.5 | 193.4 | 202.8 | 216.8 | 231.7 | 248.2 | 267.3 | 289.3 | 7.4 |
| OTHER END USERS | 32.1 | 32.6 | 33.4 | 34.9 | 36.5 | 38.2 | 40.1 | 42.4 | 4.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 52 | 53.7 | 56.2 | 59.9 | 63.8 | 68.2 | 73.3 | 79.1 | 7.1 |
| TOTAL | 358.6 | 370.4 | 387.3 | 412.6 | 439.3 | 469.2 | 503.6 | 543.1 | 7 |
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need US market intelligence to optimize product portfolios, understand adoption rates of molecular cytogenetics platforms, and identify opportunities for market expansion and technology differentiation.
- Clinical Laboratory Directors : Laboratory leaders require market data to benchmark their molecular cytogenetics capabilities against industry standards, justify capital investments in new technologies, and plan service expansion strategies.
- Healthcare Investment Firms : Investors need comprehensive US market analysis to evaluate investment opportunities in diagnostic companies, assess market growth potential, and make informed decisions on healthcare technology acquisitions.
- Hospital & Health System Administrators : Healthcare administrators need market insights to understand molecular cytogenetics demand, evaluate vendor solutions, plan diagnostic service offerings, and allocate budgets for genetic testing infrastructure.
- Regulatory & Compliance Consultants : Consultants require detailed US market data to advise clients on regulatory requirements, reimbursement strategies, and market positioning for molecular cytogenetics products and services.
Key Companies in the US Molecular Cytogenetics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| TRANSGENOMIC, INC. | United States | Public Company | ICE COLD-PCR and Multiplexed ICE COLD-PCR reagents,Oncology clinical testing services,Pharmacogenomics and clinical trial support services, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips and analyzers, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science tools & reagents (genomics, oncology, drug discovery),Software, informatics, and subscriptions, |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read instruments and consumables (Onso and related kits), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Tools,Other / Services and Software, |
| BIO-TECHNE | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology, |
| GENE DX, LLC | United States | Public Company | Pediatric and rare disease exome/genome diagnostics,Hereditary risk and cancer testing,Data and information services / AI-based platforms, |
| INSIGHT MOLECULAR DIAGNOSTICS INC. | United States | Public Company | Oncology LDTs and clinical tests (DetermaCNI, DetermaIO, other oncology assays),Transplant monitoring (GraftAssureCore, GraftAssureIQ, GraftAssureDx),Biomarker discovery, assay development, and clinical trial support services, |
| BIOVIEW | Israel | Public Company | Accord & Accord Plus workbench and automatic fluorescent imaging systems,Allegro Plus chromosomal aberration imaging systems,DUET-3 and DeNovo CTC and multi-application imaging platforms, |
TRANSGENOMIC, INC.
TransGenomic, Inc. is a United States-based public company founded in 1997 with 19 employees operating in the genetic analysis and diagnostics sector.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a Japanese public company established in 1939 with 696 employees, engaged in chemical and diagnostic product manufacturing.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.
ABBOTT
Abbott is a United States-based public company founded in 1888 with 115,000 employees operating in pharmaceuticals, diagnostics, and medical devices.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical services.
ILLUMINA, INC.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees specializing in DNA sequencing and genetic analysis technologies.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees providing analytical instruments and life sciences solutions.
PACBIO
PacBio is a United States-based public company founded in 2000 with 485 employees developing long-read DNA sequencing technologies.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing life science research and clinical diagnostics products.
BIO-TECHNE
Bio-Techne is a United States-based public company founded in 1976 with 3,100 employees providing protein reagents and tools for life sciences research.
GENE DX, LLC
GeneDx, LLC is a United States-based public company founded in 2000 with 1,300 employees specializing in genetic testing and diagnostics.
INSIGHT MOLECULAR DIAGNOSTICS INC.
Insight Molecular Diagnostics Inc. is a United States-based public company founded in 2009 with 57 employees providing molecular diagnostic testing services.
BIOVIEW
BioView is an Israel-based public company founded in 1998 with 30 employees developing imaging and analysis technologies for genetic diagnostics.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise valuation metrics for the US market ($182.6M in 2025) with detailed 5-year forecasts, enabling accurate financial planning and investment decisions for diagnostic companies and healthcare providers.
- Competitive Landscape Analysis : Understand the US-specific competitive dynamics, key market players, and their strategic positioning within the molecular cytogenetics sector to identify partnership and acquisition opportunities.
- Regulatory & Reimbursement Insights : Gain comprehensive understanding of US FDA regulations, insurance coverage policies, and reimbursement trends that directly impact market adoption and pricing strategies for molecular cytogenetics solutions.
- Technology Adoption Trends : Identify which molecular cytogenetics technologies (FISH, array-CGH, NGS) are gaining traction in US clinical laboratories and hospitals, informing product development and market entry strategies.
- Growth Driver Identification : Discover specific US market drivers including cancer screening initiatives, prenatal testing expansion, and precision medicine adoption to align business strategies with high-growth segments and emerging opportunities.
Frequently asked questions
What is the current size of the US Molecular Cytogenetics Market?
The US Molecular Cytogenetics Market is valued at $182.6 million in 2025.
What is the projected size of the US market by 2030?
The US Molecular Cytogenetics Market is projected to reach $260.5 million by 2030.
What is the growth rate of the US Molecular Cytogenetics Market?
The US market is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2030.
What factors are driving growth in the US Molecular Cytogenetics Market?
Key drivers include rising cancer incidence, increased adoption of genetic testing, clinical laboratory automation, and strong healthcare infrastructure investment in the US.
Which applications dominate the US Molecular Cytogenetics Market?
The US market is primarily driven by oncology, prenatal diagnosis, and hematology applications, with oncology representing the largest segment.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global molecular cytogenetics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the molecular cytogenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochemistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global molecular cytogenetics market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the molecular cytogenetics market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Molecular cytogenetics is the study of chromosomes at all stages of the cell cycle. It comprises a set of techniques, including chromogenic in situ hybridization (CISH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization. In molecular cytogenetics, various techniques are employed to label DNA probes with fluorescent tags, allowing for the observation of one or multiple specific regions of the genome. Cytogenetic techniques are used to analyze genomic structures and variations at the chromosomal level. Molecular cytogenetics has its applications in the fields of oncology, personalized medicine, and genetic disorders.
The study offers an in-depth analysis of the molecular cytogenetics market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key molecular cytogenetics product providers.
Stakeholders
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- Pharmaceutical & biopharmaceutical companies
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the molecular cytogenetics market based on product & service, technique, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular cytogenetics market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the molecular cytogenetics market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the molecular cytogenetics market
- To benchmark players within the molecular cytogenetics market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Molecular Cytogenetics Market Report
Full forecast, segment splits, and company analysis for all Molecular Cytogenetics Market.
- Rest Of Europe Molecular Cytogenetics Market
- Rest Of Asia Pacific Molecular Cytogenetics Market
- Rest Of Latin America Molecular Cytogenetics Market
- Kingdom Of Saudi Arabia Molecular Cytogenetics Market
- Rest Of GCC Countries Molecular Cytogenetics Market
- Canada Molecular Cytogenetics Market
- Germany Molecular Cytogenetics Market
- UK Molecular Cytogenetics Market
- France Molecular Cytogenetics Market
- Italy Molecular Cytogenetics Market
- Spain Molecular Cytogenetics Market
- China Molecular Cytogenetics Market
- Japan Molecular Cytogenetics Market
- India Molecular Cytogenetics Market
- Australia Molecular Cytogenetics Market
- South Korea Molecular Cytogenetics Market
- Brazil Molecular Cytogenetics Market
- Mexico Molecular Cytogenetics Market
- UAE Molecular Cytogenetics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
